Product Name: Recombinant Human Serpin A1 (C-6His) Catalog #: PHH1494



Summary

Name Serpin A1/a1-Antitrypsin

Purity Greater than 95% as determined by reducing SDS-PAGE

Endotoxin level <1 EU/μg as determined by LAL test.

Construction Recombinant Human Serine Protease Inhibitor-clade A1 is produced by our

Mammalian expression system and the target gene encoding Glu25-Lys418 is

expressed with a 6His tag at the C-terminus.

Accession # AAH11991.1

Host Human Cells

Species Human

Predicted Molecular Mass 45.35 KDa

Formulation Lyophilized from a 0.2 µm filtered solution of 20mM Tris-HCl, 150mM NaCl, 2mM

CaCl2, pH 7.5.

Shipping The product is shipped at ambient temperature. Upon receipt, store it

immediately at the temperature listed below.

Stability&Storage Store at \leq -70°C, stable for 6 months after receipt. Store at \leq -70°C, stable for 3


months under sterile conditions after opening. Please minimize freeze-thaw

cycles.

Reconstitution Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is

not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. Always centrifuge tubes before opening. Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100µg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

SDS-PAGE image



Background

Product Name: Recombinant Human Serpin A1 (C-6His) Enkilife Catalog #: PHH1494

Alternative Names

Alpha-1-Antitrypsin; Alpha-1 Protease Inhibitor; Alpha-1-Antiproteinase; Serpin A1; SERPINA1; AAT; PI

Background

Serpin A1 is a prototype member of the Serpin superfamily of the serine protease inhibitors. As one of the most abundant proteinase inhibitors in the circulation, it is synthesized in hepatocytes, and to a lesser extent, in macrophages as well as intestinal epithelial cell lines and secreted as the abundant proteinase inhibitor in the circulation whose targets include elastase, plasmin, thrombin, trypsin, chymotrypsin, and plasminogen activator. Point mutations in the native SerpinA1 variants result in Serpin A1 deficiency, and consequently lead to several clinical complications such as pulmonary emphysema, juvenile hepatitis, cirrhosis, and hepatocellular carcinoma. For example, the Z variants (Glu342 to Lys) forms intracellular inclusion bodies, is not secreted, and leads to a severe SerpinA1 deficiency. Accordingly, Serpin A1 deficiency in circulation is associated with emphysema or liver disease.

Note

For Research Use Only, Not for Diagnostic Use.

Web: https://www.enkilife.com E-mail: order@enkilife.com techsupport@enkilife.com Tel: 0086-27-87002838